|Bid||24.00 x 800|
|Ask||0.00 x 1400|
|Day's Range||26.40 - 26.98|
|52 Week Range||24.77 - 49.25|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||13.70|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.71|
Does the October share price for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reflect what it's really worth? Today...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
ROCKVILLE, Md., Sept. 25, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment.
Anyone researching Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) might want to consider the historical volatility of...
The market continues to ebb and flow with the direction of trade tensions. Yesterday, markets rallied strongly on some encouraging remarks from the Chinese delegation about the prospects for further trade talks.
President, CEO of Supernus Pharmaceuticals Inc (30-Year Financial, Insider Trades) Jack A. Khattar (insider trades) bought 7,200 shares of SUPN on 08/23/2019 at an average price of $26.39 a share. Continue reading...
ROCKVILLE, Md., Aug. 26, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Supernus (SUPN) delivered earnings and revenue surprises of 8.93% and -3.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Total revenue of $104.7 million, a 5.2% increase over 2018Net product sales of $102.4 million, a 5.5% increase over 2018Operating earnings of $42.6 million, a 19.3% increase.
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
ROCKVILLE, Md., July 23, 2019 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
Supernus Pharmaceuticals Inc NASDAQ NMS:SUPNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding SUPN are favorable, with net inflows of $2.29 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
In March 2019, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings update. Generally, analysts seem...
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...